Navigation Links
Amarillo Biosciences Issues Corporate Update
Date:10/14/2011

AMARILLO, Texas, Oct. 14, 2011 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today provided an update on company activities.

Oral Interferon Phase 2 Hepatitis C Study Nearing CompletionABI's oral interferon research continues. Results from a Phase 2, dose-ranging study of oral interferon for the prevention of relapse in hepatitis C patients are expected in the first quarter of 2012. A Phase 2 study of oral IFN, in combination with Tamiflu, for the treatment of influenza infection will be conducted during the upcoming flu season in Taiwan. Results are expected in the third quarter of 2012.

New Oral Interferon Studies Planned in Hepatitis B and CancerTwo new oral interferon studies are expected to start in 2012. The first will be a Phase 2 study for treatment and prevention of relapse in patients with chronic hepatitis B infection. The second will be a pilot trial to evaluate oral interferon as adjunctive therapy for certain types of cancer.

Launch of Product to Enhance Health of Animals in Shelters Planned by Year's EndThere are approximately 3,500 animal shelters in the United States. Whenever animals from different sources and backgrounds, and often with an incomplete vaccination history, are placed into these shelters, upper respiratory illness (URI) with severe cough and fever is a common occurrence. Digestive tract infections also frequently develop in these shelters. Both URI and diarrhea cause severe illness and an unacceptably high rate of death in sheltered animals.

ABI's goal is to provide a product to help address these common health problems afflicting the nation's animal shelters. More than 20 years of research and observations have resulted in the creation of an inexpensive oral formulation that can be given to companion animals upon arrival at shelters to improve their health and enhance their immunity. Product launch is expected by the end of the year.

About Amarillo Biosciences
Amaril
'/>"/>

SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biologics ... their offering. , The Global ... professional and in-depth study on the current state ... The report provides a basic overview of the ...
(Date:3/4/2015)... Bruno, CA. (PRWEB) March 04, 2015 ... (CRO) headquartered in the San Francisco Bay Area, will ... Trials (OCT) Israel Conference 2015 on March 25th ... Clinical seeks to build relationships with Israeli life science ... (FDA) clinical trials. The company’s services span all phases ...
(Date:3/4/2015)... 4, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... pain, today announced that it will release fourth ... close on Monday, March 9th, 2015. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3
... Sweden, February 21 With two successful,international ... a new expansion phase. The share issue ... number of significant product,launches in 2008-2009. These ... leading global pharmaceutical companies to meet the,industry,s ...
... 21, Shire plc (LSE: SHP, NASDAQ: SHPGY) the global,specialty biopharmaceutical company announces results for ... in launched,products., - All $ values are US$ Financial ... ... - Product sales up 55% to ...
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life Sciences ... the science of healthy aging, today announced,that Dr. ... Annual South,Beach Symposium in Miami., In his ... outlined the attributes of Pyratine-6(TM) for the treatment ...
Cached Biology Technology:Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 2Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 3Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 4Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 5Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 6Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 7Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 8Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 9Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 10Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 11Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 12Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 13Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 14Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 15Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 16Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 17Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 18Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 19Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 20Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 21Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 22Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 23Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 24Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 25Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 26Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 27Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 28Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 29Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 30Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 31Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 32Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 33Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 2Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 3
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Angeles, London, New Delhi, and Singapore (April 14, 2008) ... consumption is not related to overweight in children, according ... Between 100% Fruit Juice Consumption and Weight in Children ... Journal of Lifestyle Medicine (AJLM), published by SAGE. ...
... first study to determine the global threat status of ... reveals serious overfishing and recommends key steps that governments ... for action are published in the latest edition of ... study, organised by the IUCN Shark Specialist Group (SSG), ...
... ON According to the World Health Organization, water ... the world and population growth, urbanization and increased domestic ... By examining the relationship between global warming and ... hopes to help protect future water resources. Western ...
Cached Biology News:New research: Fruit juice consumption not related to overweight in children 2Over 50 percent of oceanic shark species threatened with extinction 2Researcher strives for watershed moment 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
TAR DNA binding protein...
... Star strains are high-performance ... improved protein yield in ... (Figure 1). Because the ... mRNA more rapidly than ...
Biology Products: